AbbVieABBV
NYSE · USA · Segment 2 of 8 in the Medicine, pharma & life science value chain: Big pharma
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Big pharma: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Key metrics
Market cap
$443B
Price
$264.52
Today
−0.2%
Return YTD
+16.0%
Return 1Y
+26.5%
P/E
70.2
P/S
6.9
P/B
312.1
Data as of 2026-08-25 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Skyrizi & Rinvoq (immunology)
- Oncology portfolio
- Botox & aesthetics (Allergan)
Competitors
Risks
- Humira patent loss
- Pipeline dependence
Supply chain
Supplies →
← Suppliers
Same segment: Big pharma
Compare ABBV
See where AbbVie sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →